Login / Signup

Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial.

D ThaçiA M SolimanK EyerichAndreas PinterM SebastianK UnnebrinkS RubantD A WilliamsP Weisenseel
Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2021)
Risankizumab provides significant benefits over FAEs in improving PROs across several dimensions in patients with moderate to severe psoriasis.
Keyphrases
  • patient reported outcomes
  • clinical trial
  • high intensity
  • early onset
  • coronary artery disease
  • drug induced
  • stem cells
  • randomized controlled trial
  • phase ii
  • bone marrow